Description |
SPT-IN-1 (compound 1) is an orally active and potent SPT (serine palmitoyl transferase) inhibitor, with an IC50 of 5.19 nM for hSPT1. SPT-IN-1 can be used for type 2 diabetes and dyslipidemia research[1].
|
Related Catalog |
|
Target |
IC50: 5.19 nM (hSPT1)[1]
|
In Vitro |
SPT-IN-1 (compound 1) exhibits a dose-dependent inhibition of C14-serine incorporation into ceramide in MCF-7 cells, with EC50 of 0.98 μM[1].
|
In Vivo |
SPT-IN-1 (compound 1) (Sprague Dawley rats, 0-60 mg/kg, Orally, twice daily for 7 days) dose-dependently reduces plasma ceramides, reduces triglycerides and raises HDL in cholesterol/cholic acid fed rats[1].
|
References |
[1]. Genin MJ, et al. Imidazopyridine and Pyrazolopiperidine Derivatives as Novel Inhibitors of Serine Palmitoyl Transferase. J Med Chem. 2016;59(12):5904-5910.
|